# Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

> **NCT04665284** · PHASE4 · COMPLETED · sponsor: **Getz Pharma** · enrollment: 244 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Usual care group

## Key facts

- **NCT ID:** NCT04665284
- **Lead sponsor:** Getz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-01
- **Primary completion:** 2020-09-15
- **Final completion:** 2020-09-28
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2020-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665284, "Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04665284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*